Abstract 4086: Rosiglitazone Induced Changes in the Hemodynamic Profile of Patients Assessed by Impedance Cardiography
BACKGROUND: Rosiglitazone is a thiazolidinedione (TZD), an oral antihyperglycemic agent that facilitates insulin action and thereby decreases insulin resistance in type 2 diabetics. Despite TZDs promising effects, their use has become limited by potential cardiac side-effects and they remain contraindicated in class III and IV heart failure patients.
OBJECTIVE: To determine the hemodynamic effects of rosiglitazone among diabetics using impedance cardiography (ICG), a novel noninvasive technology tool.
METHODS: The study included 60 adults (ages 44– 82) with known diabetes who have not been previously treated with thiazolidinediones. Baseline ICG data was collected prior to initiating Rosiglitazone therapy and at four week intervals. The average follow up was 9.4 weeks (4–16 weeks) and the average dose used was 5.23 mg (2– 8mg). Changes in outcome parameters were analyzed using dependent t-tests with P <0.05 level indicating statistical significance. Hemodynamics studied: 1. Standard Vital Signs (HR, SBP, DBP, MAP); 2. Blood Flow (CI, SI); 3. Vascular Resistance (SVRI); 4. Indicators of Cardiac contractility (STR); 5. Intrathoracic Fluid content (TFC); 6. Reflection of Myocardial Oxygen Demand(LCWI).
RESULTS: CONCLUSION: Intermediate term hemodynamic changes induced by Rosiglitazone were favorable, and an improvement in contractile parameters was seen. Despite these favorable changes an increase in thoracic fluid content occurred.